CD70 and acute myeloid leukemia: In this regard, a breakthrough was recently achieved for cusatuzumab (ARGX-110), an anti-CD70 targeting antibody, in combination with Azacitidine in a Phase 1/2 trial in acute myeloid leukaemia (AML).